Telesis Bio Yönetim

Yönetim kriter kontrolleri 2/4

Telesis Bio CEO'su Eric Esser, Jun2022 tarihinde atandı, in görev süresi 2.42 yıldır. in toplam yıllık tazminatı $ 683.56K olup, şirket hissesi ve opsiyonları dahil olmak üzere 62.2% maaş ve 37.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.015% ine doğrudan sahiptir ve bu hisseler $ 336.43 değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.2 yıl ve 0.3 yıldır.

Anahtar bilgiler

Eric Esser

İcra Kurulu Başkanı

US$683.6k

Toplam tazminat

CEO maaş yüzdesi	62.2%
CEO görev süresi	2.4yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	2.2yrs
Yönetim Kurulu ortalama görev süresi	less than a year

Son yönetim güncellemeleri

Recent updates

The Market Lifts Telesis Bio, Inc. (NASDAQ:TBIO) Shares 38% But It Can Do More

Apr 17

Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance

Aug 09

Codex DNA, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 25

Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space

Jan 06

Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021

Sep 24

CEO Tazminat Analizi

Eric Esser'un ücretlendirmesi Telesis Bio'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$51m
Mar 31 2024	n/a	n/a	-US$47m
Dec 31 2023	US$684k	US$425k	-US$49m

Tazminat ve Piyasa: Eric 'ın toplam tazminatı ($USD 683.56K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 651.15K ).

Tazminat ve Kazançlar: Eric şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Eric Esser (56 yo)

2.4yrs

Görev süresi

US$683,564

Tazminat

Mr. Eric Esser serves as President of Telesis Bio, Inc. since May 1, 2023 and serves as its CEO & Director since April 18, 2024. He serves as Chief Operating Officer at Telesis Bio, Inc. (formerly known as...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Eric Esser	President	2.4yrs	US$683.56k	0.015% $ 336.4
William Kullback	Chief Financial Officer	1.3yrs	Veri yok	Veri yok
Daniel Gibson	Chief Technology Officer	6.3yrs	US$1.33m	0.29% $ 6.5k
Jen Carroll	Vice President of Investor Relations	1.9yrs	Veri yok	Veri yok
Decky Goodrich	Senior Vice President of Corporate Development	no data	Veri yok	Veri yok
Richard Lepke	Director of Investor Relations	no data	Veri yok	Veri yok

2.2yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: TBIO 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Eric Esser	President	less than a year	US$683.56k	0.015% $ 336.4
Gregory Herrema	Independent Director	1.1yrs	US$254.30k	0% $ 0
Stephen Schoenberger	Member of Strategic Advisory Board	no data	Veri yok	Veri yok
Aaron Miller	Member of Strategic Advisory Board	no data	Veri yok	Veri yok
Andrea Jackson	Independent Director	3.5yrs	Veri yok	Veri yok
James Weissman	Director	less than a year	Veri yok	Veri yok
Sarah Hlavinka	Director	less than a year	Veri yok	Veri yok
Michael Hodges	Director	less than a year	Veri yok	Veri yok
Steven Golub	Director	less than a year	Veri yok	Veri yok
Todd Krueger	Director	less than a year	Veri yok	Veri yok

0.3yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TBIO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 0.3 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Telesis Bio Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Telesis Bio, Inc. Announces Chief Executive Officer Changes

Telesis Bio, Inc., Annual General Meeting, May 01, 2024

Telesis Bio, Inc. Announces Board Changes

Telesis Bio Inc. Appoints William J. Kullback Chief Financial Officer

Telesis Bio, Inc. Appoints Paul Meister as Director

Telesis Bio, Inc., Annual General Meeting, Jul 06, 2023

Recent updates

Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

Yuan (Terry) Yang entered into an agreement to acquire Eton Bioscience, Inc. from Telesis Bio, Inc. (NasdaqGS:TBIO) for $1.5 million

Telesis Bio Receives Non-Compliance Letter from Nasdaq

Telesis Bio Announces Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Global Select Market

Telesis Bio, Inc. Announces Chief Executive Officer Changes

Telesis Bio, Inc., Annual General Meeting, May 01, 2024

Telesis Bio, Inc. Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Telesis Bio Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Pursuant to Nasdaq Listing Rule 5450(a)(1) for Continued Listing on The Nasdaq Global Select Market

Telesis Bio, Inc. Provides Earnings Guidance for 2023

Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement

Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement

Telesis Bio, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Telesis Bio, Inc. Announces Board Changes

Telesis Bio Inc. Appoints William J. Kullback Chief Financial Officer

No longer forecast to breakeven

Second quarter 2023 earnings: EPS exceeds analyst expectations

Telesis Bio, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Telesis Bio, Inc. Appoints Paul Meister as Director

Telesis Bio, Inc. announced that it has received $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor

Telesis Bio, Inc. announced that it expects to receive $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm

Telesis Bio, Inc., Annual General Meeting, Jul 06, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

The Market Lifts Telesis Bio, Inc. (NASDAQ:TBIO) Shares 38% But It Can Do More

Forecast to breakeven in 2025

Consensus estimates of losses per share improve by 17%

Forecast to breakeven in 2025

Telesis Bio Releases BioXp Select mRNA Synthesis Kit to Expand the Utility, Speed, and Impact of Its Automated Synthetic Biology Workstation

Telesis Bio Provides Revenue Guidance for the Fourth Quarter of 2022

President recently bought US$192k worth of stock

Price target decreased to US$6.50

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Telesis Bio, Inc. Revises Revenue Guidance for the Full Year 2022

Telesis Bio, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Codex DNA, Inc. Announces Resignation of Brent Hunter as Vice President, Finance

Codex DNA, Inc. Expands Application of Proprietary Error Correction Technology

Codex DNA Showcases Next Generation Automated Synthetic Biology Workstation at World of Technology & Science in Utrecht, Netherlands

Codex Dna Debuts Next-Generation Automated Synthetic Biology Workstation

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Codex DNA, Inc. Raises Revenue Guidance for the Full Year of 2022

Codex DNA GAAP EPS of -$0.50, revenue of $5.7M; raises FY22 guidance

Codex DNA, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Codex DNA, Inc. Appoints Annette Tumolo to Serve as A Class III Director

Codex DNA, Inc.(NasdaqGS:DNAY) dropped from Russell 2500 Value Index

Codex DNA, Inc. Appoints Eric Esser to Serve as the Chief Operating Officer

Codex DNA Showcases Automated Synthetic Biology Solutions for Accelerating Discovery Workflows at the Antibody Engineering and Therapeutics Europe Conference

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Codex DNA, Inc. to Report Q1, 2022 Results on May 10, 2022

Codex DNA, Inc., Annual General Meeting, Jun 09, 2022

High number of new and inexperienced directors

Codex DNA Demonstrates End-to-End Workflow for Storing and Retrieving Data in Synthetic DNA

Codex Dna, Inc. Demonstrates Simple, Scalable, and Cell-Free Approach to Rapid mRNA Vaccine Design and Development At World Vaccine Congress Washington 2022

Codex DNA, Inc. (NASDAQ:DNAY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Codex DNA, Inc. to Report Q4, 2021 Results on Mar 22, 2022

Codex DNA, Inc. Showcases Potential of SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Vaccines and Therapeutics

Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This Space

High number of new and inexperienced directors

Codex DNA, Inc. Expands Catalog of COVID-19 Tools with Release of Full-Length Synthetic Genome for SARS-CoV-2 Omicron Variant

Codex DNA, Inc. Announces Commercial Availability of Automated mRNA Synthesis Kit with Integrated Capping Technology for BioXp™ System

Third quarter 2021 earnings released: US$0.34 loss per share

Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021

Senior Vice President of Commercial Operations Timothy Cloutier has left the company

Codex DNA, Inc. has completed an IPO in the amount of $106.66664 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi